NRG Therapeutics Ltd

Based in Stevenage, UK, and founded in 2018 by CEO and co-founder Dr. Neil Miller, NRG Therapeutics Ltd. operates as a drug discovery company that offers therapeutic approaches to restore mitochondrial function and prevent the progression of neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, and motor neurone disease. In September 2025, NRG Therapeutics Ltd.

raised GBP 50 million in series B funding from led by new investor SV Health Investors, with participation from other new investors British Business Bank, M Ventures, Novartis Venture Fund, and Criteria Bio Ventures. Returning investors Criteria Bio Ventures and Brandon Capital Partners also participated in the round. The company is developing second-generation mitochondrial permeability transition pore (mPTP) inhibitors to prevent the pathological effects of misfolded TDP-43 and a-synuclein, two toxic proteins that cause the degeneration of motor neurones and dopaminergic neurones in ALS and Parkinson’s respectively. The company plans to utilize the September 2025 funding to demonstrate clinical proof of concept in ALS/MND and obtain Phase 1b data in Parkinson’s patients.